Inhibrx Biosciences, Inc. Income Statement

Income Statement Dec2023 Dec2024
Revenue & cost
Revenue 1.80M0.20M
Gross Profit 1.80M0.20M
Operating items
Research & Development 191.64M203.74M
Selling, General & Administrative 29.38M127.91M
Operating Expenses 221.02M331.65M
Operating Income -219.22M-331.45M
EBIT -219.22M-331.45M
Non-operating items
Interest & Investment Income 11.92M10.94M
Other Non Operating Income -0.58M0.07M
Non Operating Income -20.50M2019.02M
Net income details
EBT -239.72M1687.57M
Tax Provisions 0.00M0.00M
Profit After Tax -241.36M1687.57M
Equity Income -1.63M
Income from Continuing Operations -239.73M1687.57M
Consolidated Net Income -239.73M1687.57M
Income towards Parent Company -239.73M1687.57M
Net Income towards Common Stockholders -239.73M1687.57M
Additional items
EPS (Basic) -0.00M0.00M
EPS (Weighted Average and Diluted) -0.00M0.00M
Shares Outstanding (Weighted Average) 13.38M14.48M
Shares Outstanding (Diluted Average) 11.78M14.98M
EBITDA -219.22M-331.45M
Tax Rate 0.00M